Chronic clinically unapparent chorioamnionitis is a common antenatal exposure for very preterm infants, and these infants have variable degrees of lung maturation and a high risk of developing bronchopulmonary dysplasia. Exposure of fetal sheep to intra-amniotic endotoxin or IL-1a induces chorioamnionitis and lung injury (decreased alveolarization and microvascular injury), which resolves to a phenotype of striking lung maturation (increased surfactant, improved gas exchange and lung mechanics). The immune responses of the fetus also are suppressed or induced (matured) in time and dose-dependent ways by either chorioamnionitis or antenatal corticosteroids. These experimental observations contribute to explanations of why preterm infants have variable degrees of lung maturation at birth and unpredictably develop bronchopulmonary dysplasia BPD.
The clinician has two primary lung-related concerns when faced with an infant born before 30 weeks gestation F minimizing the problems resulting from lung immaturity (respiratory distress syndrome F RDS) and avoiding progressive lung injury (bronchopulmonary dysplasia F BPD). This review will focus on the complex relationships between RDS, BPD and chorioamnionitis as they are recognized clinically and as presently understood from animal models.
Human Fetal Lung Development F The Substrate
The fetal lung does not normally mature functionally until after 35 to 36 weeks, when surfactant is present in large amounts. However, normal physiologic function does not mean a mature anatomy.
The fetal lung is in the saccular stage of development from about 24 weeks gestation until secondary septation begins the process of alveolarization at about 32 weeks gestation. 1 Alveolarization occurs in parallel with microvascular development, primarily between about 32 weeks gestation and several months after term birth. The practical consequence of the timing of this late gestational lung structural development is that the very low birth weight (VLBW) infant is born with the lung in the saccular stage of lung development. This lung must develop postnatally while supporting gas exchange and other metabolic functions. While RDS is more complex than simply surfactant deficiency, the striking effectiveness of surfactant therapy even at very early gestational ages mitigates many of the clinical problems of managing the preterm lung soon after birth. 2 Lung maturation also is inducible with antenatal glucocorticoid therapy, which further decreases the risk of severe lung immaturity. 3 Lung structural maturation (alveolarization and microvascular development) may not be inducible and, in fact, alveolarization is delayed by glucocorticoids, inflammation, oxygen, mechanical ventilation and nutritional deficiency. 4 Therefore, interventions used to maintain virtually all VLBW infants tend to disrupt normal lung development.
BPD in VLBW infants is the net result of lung injury, repair and disrupted development that should be viewed as a sequence of adverse events or ''hits'' (Figure 1 ). Although infants with BPD have chronic lung inflammation, decreased alveolar septation and decreased microvascular development, the amount of fibrosis and reversibility or recovery potential of the lung is quite variable. BPD describes a wide spectrum of disease severity resulting from the multiple factors contributing to disease progression. A factor that is usually not clinically recognized or considered is antenatal exposure of the fetus to inflammation.
Chorioamnionitis F What is it?
Traditionally, chorioamnionitis was considered to be an acute infection of the fetal compartment with highly pathologic organisms, generally in late gestation or after rupture of membranes. 5 In contrast, many VLBW infants are born after the onset of spontaneous labor or preterm rupture of membranes to women without symptoms of chorioamnionitis. However, more than 70% of unruptured women in preterm labor who deliver before 30 weeks gestational age will have cultures of amniotic fluid or membranes that are positive for low pathogenic organisms. 5 Similar percents of all women delivering prior to 30 weeks gestation will have histologic chorioamnionitis. 6, 7 Amniotic fluid of women in early preterm labor often contains inflammatory cells and proinflammatory cytokines, although the women are asymptomatic. 8 Many of these women may have had low-grade chorioamnionitis for weeks or months before the preterm labor. The Venn diagram illustrates the diagnostic dilemma (Figure 2 ). Chorioamnionitis includes overlapping populations of patients with histologic chorioamnionitis and clinical chorioamnionitis with subpopulations of infants that may have a systemic inflammatory response or sepsis. Organisms may be identified without other signs of infection in some women. There have been no systemic studies of the duration or intensity of the antenatal inflammatory exposure of VLBW infants. The important conclusion is that the majority of VLBW infants have been exposed to some antenatal inflammation. Nevertheless, the incidence of sepsis defined as a positive blood culture is less than 3% and a clinical diagnosis of ''congenital'' pneumonia is seldom made in VLBW infants. 
Clinical Associations With Chorioamnionitis in VLBW Infants
A remarkable observation is that many VLBW infants do not have severe lung immaturity and some of these infants have no RDS. 10 While antenatal corticosteroids can decrease RDS by about 50%, the effects of corticosteroids in large animal models are modest.
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Clinical experience suggests that something else is inducing very early lung maturation in many VLBW infants. Watterberg et al. 12 reported that ventilated infants exposed to histologic chorioamnionitis had less RDS but more BPD than control infants. In one report, ureaplasma colonization at birth was associated with less RDS. 13 There has been no prospective study that evaluates both the characteristics of the chorioamnionitis and the pulmonary outcomes in VLBW infants in any detail. The lung outcomes are likely to depend on the type, duration and intensity of the chorioamnionitis as well as other therapies such as corticosteroids. For example, Van Marter et al. 14 found that chorioamnionitis decreased the risk of BPD unless the infant was also mechanically ventilated. The combination of ventilation and chorioamnionitis increased the risk of BPD.
Lessons from Animal Models of Chorioamnionitis
The first experimental demonstration that fetal exposure to inflammation might modulate lung maturation was the report of Bry et al. 15 that intra-amniotic injections of IL-1 induced lung maturation in fetal rabbits. Intra-amniotic injections of endotoxin also induce striking lung maturation in fetal sheep. 16 The maturation response (increased surfactant, improved compliance and gas exchange, thinning of the lung mesenchyme) occurs after a phase of acute lung injury (increased inflammatory cells, proinflammatory cells and edema). 17 The maturation response is much larger than that seen with maternal corticosteroid treatment in the sheep (Figure 3 ). Lung injury followed by maturation results from the direct contact of the endotoxin with the fetal respiratory epithelium as a result of mixing of fetal lung fluid with the endotoxin in amniotic fluid. 18 Lung maturation also can be induced with the proinflammatory cytokine IL-1 or by colonizing the amniotic fluid with ureaplasma urealyticum, but intra-amniotic injections of TNFa or INFg do not induce inflammation or lung maturation in the sheep model. 19, 20 These maturation responses occur without an increase in fetal cortisol, demonstrating that inflammationmediated lung maturation occurs by pathways distinct from cortisol. 16 Chorioamnionitis is a potent inducer of lung maturation in fetal sheep.
Corticosteroids and Chorioamnionitis
In clinical practice, most women in very early preterm labor with clinically silent chorioamnionitis are treated with corticosteroids. This clinical practice is supported by clinical trial data. 21 Nevertheless, it is worth considering how chorioamnionitis and antenatal corticosteroid therapy may interact. The normal fetus is immune naïve and immune immature. Chorioamnionitis exposes the fetus to inflammation primarily via the fetal lung, which causes lung injury followed by the phenotype of lung maturation. 18 Repeated exposures of fetal sheep to endotoxin do not cause progressive lung inflammation or injury. Rather, the lung suppresses the inflammatory response. Blood monocytes from the fetal sheep have a decreased response to challenge with endotoxin in vitro 2 days after intra-amniotic exposure of the fetus F an endotoxin tolerance response 22 ( Figure 4 ). However, 7 days after the fetal exposure, the cells respond to endotoxin more like monocytes from adult ewes F a maturation effect. Two fetal endotoxin exposures 14 and 7 days before the third challenge of Figure 3 . Antenatal intra-amniotic endotoxin or maternal betamethasone exposure of fetal sheep for different intervals before preterm delivery at 125 days gestation. All values are normalized to 1.0 for control lambs. The inflammatory exposure from endotoxin caused a persistent increase in the mRNA for surfactant protein A (SP-A). In contrast, the corticosteroid effect was much less. The amount of SP-A in the alveolar wash also increased much more after endotoxin than betamethasone. Data from references. Jobe et al., 16 Ballard et al., 25 Bachurski et al., 26 Tan et al. 27 the monocytes induce a persistent endotoxin tolerance response. Thus, intra-amniotic endotoxin causes a complex modulation of the innate immunity of the fetus. Maternal corticosteroid treatment also suppresses fetal blood monocyte function below that of the already immature fetal monocyte 23 ( Figure 4) . However, monocyte function evaluated 7 days after the maternal treatment is increased above that of control adult monocytes F a maturation effect. Thus, either inflammation or corticosteroids can cause suppression or induction of fetal monocyte function, depending on the timing. If the sheep fetus is exposed to both maternal corticosteroids and intra-amniotic endotoxin at the same time, the corticosteroids initially suppress endotoxin-induced inflammation for several days but result in amplified inflammatory responses 5 or 15 days later. 24 Both corticosteroids and inflammation interact to modulate the fetal innate immune response in complicated and time-dependent ways. Inflammation is considered central to the progression of BPD. Our results suggest that fetal exposures may modulate both fetal and postnatal inflammatory responses to propagate the injuries resulting in BPD. The lung maturational effects of corticosteroids and chorioamnionitis may benefit the fetal lung by decreasing RDS, but alterations in innate immune responses may contribute to BPD.
